Try our corporate solution for free!

Time between combination therapies approval and patient access in Europe 2022

Average time between marketing authorization and patient access for combination therapies in Europe as of 2022, by country

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

April 2022

Region

Europe

Survey time period

as of January 1, 2022

Supplementary notes

Data collected is for drugs launched from 2017 to 2020. In most countries availability equates to granting of access to the reimbursement list, except in DK, FI, NO, SE some hospital products are not covered by the general reimbursement scheme. The time to availability (previously known as length of delay) is the days between EMA marketing authorisation and the date of availability to patients.

* These countries did not complete a full dataset and therefore availability may be unrepresentative.
** The source mentions that it does not take into account France's system of temporary authorization for some products, which means this time will be higher than in reality.
*** MHRA’s Early Access to Medicines Scheme provides access prior to marketing authorization but is not included within this analysis, and would reduce the overall days for a small subset of medicines.

Citation formats
Statista Accounts: Access All Statistics. Starting from $468 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 USD $39 USD / Month *
in the first 12 months
Professional Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on " Pharmaceutical industry in China "

Statistics on Pharmaceutical industry in China

Key Figures

7

Drug evaluation and approval

8

Sales channels

7

Pharmaceutical enterprises

7

Further related statistics

18
Statista Accounts: Access All Statistics. Starting from $468 USD / Year
Learn more about how Statista can support your business.